Articles published by ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ASX:CSL CSLLY SPRY
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.